The Kenilworth, N.J.-based drugmaker posted sales of $314 million for Keytruda in the second quarter.
Merck’s new hepatitis C drug Zepatier reported sales of $112 million for the second quarter. The drug was approved by the Food and Drug administration last January.
Merck recorded a second quarter profit of $1.21 billion, or 43 cents a share, compared to $687 million, or 24 cents a share, in the same quarter the year prior.
Sales grew 0.6 percent to $9.84 billion this quarter, compared to $9.78 billion in the second quarter of 2015.
Merck now expects per-share adjusted earnings between $3.67 and $3.77 for the year with revenue between $39.1 billion and $40.1 billion. Thomson Reuters analysts had expected adjusted earnings of $3.72 a share and a revenue of $39.5 billion.
More articles on the drug market:
Eli Lilly CEO to retire
FDA approves AbbVie’s drug to treat chronic hepatitis C
‘Pain refugees’ travel out of Montana for access to opioid prescriptions
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.